Six year survival in the combined treatment of far advanced head and neck cancer under a combined therapy program.
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000628:therapy*; D005069:Evaluation Studies as Topic; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D009060:Mouth Floor; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000628:therapy*; D010157:Palatal Neoplasms / Q000188:drug therapy; D011838:Radiation-Sensitizing Agents; D011855:Radiodermatitis; D011878:Radiotherapy / Q000009:adverse effects; D014067:Tonsillar Neoplasms / Q000188:drug therapy / Q000628:therapy*
D011838:Radiation-Sensitizing Agents; D006918:Hydroxyurea